| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.08% | 71.08% | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 70.98% | 70.80% | 74.54% | 76.39% | 75.24% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 14.64% | -18.53% | 17.83% | 13.71% | 15.08% | -21.20% | 13.15% | 21.81% | 4.85% | 22.94% | 9.45% | 12.62% |
| Current Ratio | 1.26 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 1.61 | 1.55 | 1.55 | 1.30 | 1.73 |
| Quick Ratio | 1.14 | 1.15 | 1.31 | 1.14 | 1.43 | 1.47 | 1.37 | 1.50 | 1.43 | 1.41 | 1.15 | 1.54 |
| Debt / Equity | 2.44 | 3.04 | 1.35 | 1.27 | 1.24 | 1.34 | 0.91 | 0.52 | 0.68 | 0.41 | 0.47 | 0.53 |
| ROE | 38.19% | -54.78% | 27.27% | 20.37% | 19.46% | -23.84% | 6.66% | 35.07% | 8.58% | 27.55% | 10.97% | 13.49% |
| ROA | 7.83% | -9.66% | 8.43% | 6.53% | 6.40% | -7.61% | 2.65% | 14.06% | 3.00% | 13.22% | 4.93% | 5.94% |
| Asset Turnover | 0.54 | 0.52 | 0.47 | 0.48 | 0.42 | 0.36 | 0.20 | 0.64 | 0.62 | 0.58 | 0.52 | 0.47 |
| Book Value / Share | 9.06 | 8.06 | 14.16 | 14.47 | 16.01 | 16.75 | 30.14 | 8.57 | 7.11 | 9.63 | 8.50 | 8.89 |
Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey, and founded in 1933. It discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines addressing serious diseases worldwide. The company offers a diverse portfolio including small molecule drugs, biologics produced from biological processes, and advanced chimeric antigen receptor (CAR-T) cell therapies. Key therapeutic areas encompass oncology with treatments like nivolumab (Opdivo) and ipilimumab (Yervoy), hematology featuring lenalidomide (Revlimid) and luspatercept (Reblozyl), immunology such as abatacept (Orencia), cardiovascular including apixaban (Eliquis), neuroscience, and other immunology and fibrosis-related conditions. Bristol-Myers Squibb Company plays a vital role in the healthcare sector by providing therapies for cancer, immune disorders, cardiovascular diseases, and beyond, serving patients through collaborations and a focus on unmet medical needs in these critical markets.